Paclitaxel biological synthesis promotes the innovation of anti-cancer drugs

References

[1] Horwitz SB. Reflections on my life with Taxol. Cell. 2019; 177(3): 502-505.

[2] Sofias AM, Dunne M, Storm G, Allen C. The battle of “nano” paclitaxel. Adv Drug Deliv Rev. 2017; 122: 20-30.

[3] Vitiello A, Ferrara F, Lasala R, Zovi A. Precision medicine in the treatment of locally advanced or metastatic urothelial cancer: new molecular targets and pharmacological therapies. Cancers. 2022; 14(20): 5167.

[4] Vil V, Terent’ev AO, Al Quntar AAA, Gloriozova TA, Savidov N, Dembitsky VM. Oxetane-containing metabolites: origin, structures, and biological activities. Appl Microbiol Biotechnol. 2019; 103(6): 2449-2467.

[5] Jiang B, Gao L, Wang H, et al. Characterization and heterologous reconstitution of Taxus biosynthetic enzymes leading to baccatin III. Science. 2024; 383(6683): 622-629.

[6] Yang C, Wang Y, Su Z, et al. Biosynthesis of the highly oxygenated tetracyclic core skeleton of Taxol. Nat Commun. 2024; 15(1): 2339.

[7] Xiong X, Gou J, Liao Q, et al. The Taxus genome provides insights into paclitaxel biosynthesis. Nat Plants. 2021; 7(8): 1026-1036.

[8] Liu JC-T, De La Pena R, Tocol C, Sattely ES. Reconstitution of early paclitaxel biosynthetic network. Nat Commun. 2024; 15(1): 1419.

[9] Boge TC, Hepperle M, Vander Velde DG, Gunn CW, Grunewald GL, Georg GI. The oxetane conformational lock of paclitaxel: structural analysis of D-secopaclitaxel. Bioorg Med Chem Lett. 1999; 9(20): 3041-3046.

[10] Rojas JJ, Bull JA. Oxetanes in drug discovery campaigns. J Med Chem. 2023; 66(18): 12697-12709.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.